These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25791861)

  • 1. Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-making.
    Godwin H; Nameth C; Avery D; Bergeson LL; Bernard D; Beryt E; Boyes W; Brown S; Clippinger AJ; Cohen Y; Doa M; Hendren CO; Holden P; Houck K; Kane AB; Klaessig F; Kodas T; Landsiedel R; Lynch I; Malloy T; Miller MB; Muller J; Oberdorster G; Petersen EJ; Pleus RC; Sayre P; Stone V; Sullivan KM; Tentschert J; Wallis P; Nel AE
    ACS Nano; 2015; 9(4):3409-17. PubMed ID: 25791861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are environmental regulations keeping up with innovation? A case study of the nanotechnology industry.
    Fairbrother A; Fairbrother JR
    Ecotoxicol Environ Saf; 2009 Jul; 72(5):1327-30. PubMed ID: 19423165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From cradle-to-grave at the nanoscale: gaps in U.S. regulatory oversight along the nanomaterial life cycle.
    Beaudrie CE; Kandlikar M; Satterfield T
    Environ Sci Technol; 2013 Jun; 47(11):5524-34. PubMed ID: 23668487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotech under scrutiny, but tighter regulation remains distant.
    Kling J
    Nat Biotechnol; 2007 Oct; 25(10):1068. PubMed ID: 17921977
    [No Abstract]   [Full Text] [Related]  

  • 5. Necessity and approach to integrated nanomaterial legislation and governance.
    Wang J; Gerlach JD; Savage N; Cobb GP
    Sci Total Environ; 2013 Jan; 442():56-62. PubMed ID: 23178764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying comprehensive environmental assessment to research planning for multiwalled carbon nanotubes: Refinements to inform future stakeholder engagement.
    Powers CM; Grieger K; Meacham CA; Gooding ML; Gift JS; Lehmann GM; Hendren CO; Davis JM; Burgoon L
    Integr Environ Assess Manag; 2016 Jan; 12(1):96-108. PubMed ID: 26011822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology and nanomaterials: toxicology, risk assessment, and regulations.
    Fan AM; Alexeeff G
    J Nanosci Nanotechnol; 2010 Dec; 10(12):8646-57. PubMed ID: 21121378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States Government Accountability Office report on nanotechnology: nanomaterials are widely used in commerce, but EPA faces challenges in regulating risk.
    United States Government Accountability Office
    Int J Occup Environ Health; 2010; 16(4):525-39. PubMed ID: 21222394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory policy. Congress moves toward strengthening EPA's hand on chemical safety.
    Stokstad E
    Science; 2010 Apr; 328(5977):417. PubMed ID: 20413468
    [No Abstract]   [Full Text] [Related]  

  • 10. Approaches to Develop Alternative Testing Strategies to Inform Human Health Risk Assessment of Nanomaterials.
    Stone V; Johnston HJ; Balharry D; Gernand JM; Gulumian M
    Risk Anal; 2016 Aug; 36(8):1538-50. PubMed ID: 27285586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century.
    Reese M
    Health Matrix Clevel; 2013; 23(2):537-72. PubMed ID: 24341081
    [No Abstract]   [Full Text] [Related]  

  • 12. Trump Administration stymies US EPA's chemical carcinogenicity and toxicity assessments.
    Furlow B
    Lancet Oncol; 2019 May; 20(5):617. PubMed ID: 30956122
    [No Abstract]   [Full Text] [Related]  

  • 13. Nanotechnology. EPA ponders voluntary nanotechnology regulations.
    Service RF
    Science; 2005 Jul; 309(5731):36. PubMed ID: 15994499
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated assessment of risk and sustainability in the context of regulatory decision making.
    Sexton K; Linder SH
    Environ Sci Technol; 2014; 48(3):1409-18. PubMed ID: 24417344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus?
    Shvedova AA; Kisin ER; Porter D; Schulte P; Kagan VE; Fadeel B; Castranova V
    Pharmacol Ther; 2009 Feb; 121(2):192-204. PubMed ID: 19103221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomaterial risk assessment and management experiences related to worker health under the Toxic Substances Control Act.
    Sayre P; Prothero S; Alwood J
    J Occup Environ Med; 2011 Jun; 53(6 Suppl):S98-102. PubMed ID: 21654427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing chemical risk: societies offer expertise.
    ; ; ; ; ; ; ;
    Science; 2011 Mar; 331(6021):1136. PubMed ID: 21385698
    [No Abstract]   [Full Text] [Related]  

  • 18. NANOtechnology: untold promise, unknown risk.
    Consum Rep; 2007 Jul; 72(7):40-5. PubMed ID: 17632953
    [No Abstract]   [Full Text] [Related]  

  • 19. Case studies putting the decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping) into practice.
    Arts JH; Irfan MA; Keene AM; Kreiling R; Lyon D; Maier M; Michel K; Neubauer N; Petry T; Sauer UG; Warheit D; Wiench K; Wohlleben W; Landsiedel R
    Regul Toxicol Pharmacol; 2016 Apr; 76():234-61. PubMed ID: 26687418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotoxicology and nanomedicine: making hard decisions.
    Linkov I; Satterstrom FK; Corey LM
    Nanomedicine; 2008 Jun; 4(2):167-71. PubMed ID: 18329962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.